Business Context and Reporting Period
This Form 8-K, dated April 15, 2021, serves as a supplemental disclosure to the Proxy Statement/Circular regarding the proposed Arrangement between Tilray, Inc. and Aphria Inc. The filing details critical developments concerning the Tilray Special Meeting originally scheduled for April 16, 2021, which was adjourned to April 30, 2021, due to concerns regarding the ability to achieve a quorum.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction mechanics; it does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The text references forward-looking estimates of approximately C$100 million in pre-tax annual cost synergies expected from the transaction but provides no historical financial data.
Material Changes and Corporate Actions
- Meeting Adjournment: The Tilray Special Meeting was adjourned from April 16, 2021, to April 30, 2021, to solicit additional proxies.
- Quorum Amendment: The Tilray Board approved an amendment to the Bylaws to reduce the quorum requirement from a majority of voting power to the statutory minimum of one-third of voting power.
- Charter Amendment Waiver: The Board approved a waiver making the Charter Amendment Proposal (increasing authorized capital stock) no longer a condition precedent to the Arrangement, should it fail to receive stockholder approval.
- Aphria Approval: Aphria shareholders approved the Arrangement on April 14, 2021.
- Proxy Status: As of April 8, 2021, proxies received were running substantially in favor of the proposals, with greater than 90% of responses supporting the Charter Amendment and Share Issuance proposals.
Guidance, Outlook, and Risks
Management Commentary: Management and the Board determined that the Quorum Amendment and Charter Amendment Waiver were necessary to facilitate a transaction deemed in the best interests of stockholders. The Board noted that failure to satisfy the quorum requirement would result in the loss of the transaction.
Outlook: The Combined Company anticipates scalable medical and adult-use cannabis platforms, a diversified product offering, and operational efficiencies. The transaction is expected to strengthen leadership positions in Canada, internationally, and eventually the United States.
Risks and Contingencies:
- Quorum Risk: Initial projections indicated it was unlikely a quorum would be met due to a large "dead block" of shares, a high number of retail stockholders, and significant trading post-record date.
- Transaction Failure: Risks include the inability to obtain necessary shareholder or court approvals, failure to satisfy closing conditions, and the possibility that expected synergies may not materialize.
- Market Conditions: Risks associated with the COVID-19 public health crisis and competitive responses to the transaction announcement.
Investor Verification Checklist
- Verify the outcome of the adjourned Tilray Special Meeting scheduled for April 30, 2021.
- Confirm whether the reduced quorum requirement (one-third) successfully enabled the meeting to proceed.
- Check if the Charter Amendment Proposal was approved or if the waiver was formally invoked.
- Review the final exchange ratio and terms of the Arrangement Agreement as executed.
- Monitor regulatory approvals required for the listing of the Combined Company on the Toronto Stock Exchange.